IGM-2537 / IGM Biosciences - LARVOL DELTA

Novel CD123xCD3 Bispecific Igm Antibody, Igm-2537, Potently Induces T-Cell Mediated Cytotoxicity of Acute Myeloid Leukemia Cells In Vivo and in Vitro with Minimal Cytokine Release (ASH 2023) - "IGM-2537 bound with high affinity and avidity to CD123. In vitro, IGM-2537 engaged both CD123 and CD3 to induce potent T-cell activation and T-cell mediated cytotoxicity of CD123+ AML cells, and autologous CD123+ basophils and plasmacytoid dendritic cells (pDCs). Though IGM-2537 demonstrated comparable maximal killing activity to a comparator IgG TCE, IGM-2537 demonstrated minimal cytokine release."

IO biomarker • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD123 • IFNG • IL3RA • TNFA

Novel CD123xCD3 bispecific IgM antibody, IGM-2537, potently induces T-cell mediated cytotoxicity of acute myeloid leukemia cells with minimal cytokine release (AACR 2023) - "In summary, IGM-2537 demonstrated potent in vitro and in vivo T-cell mediated cytotoxicity of AML cell lines with minimal cytokine induction. These preclinical data further support the clinical development of IGM-2537 for the treatment of AML and more broadly substantiate the use of IgM antibodies as a framework for TCEs to provide an improved therapeutic window for T-cell redirected therapeutics."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD123

IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023 (GlobeNewswire) - "IGM Biosciences...announced the presentation of six posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023....'We are proud to show the breadth and depth of our oncology pipeline at this year’s AACR meeting, as the emerging data from our clinical and pre-clinical efforts on IGM-8444, IGM-7354, IGM-2644, IGM-2537 and imvotamab continue to demonstrate the potential for encouraging anticancer activity coupled with favorable safety profiles'..."

Preclinical • Trial status • Acute Myelogenous Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

CD123 Directed IgM Antibody-based T-cell Engager, IGM-2537, Demonstrates Potent in vitro and in vivo Activity with Minimal Cytokine Release (ASH 2022) - "IGM-2537 bound to human CD123 with high affinity, avidity, and specificity. Furthermore, IGM-2537 bound a unique epitope of human CD123 in domain 2 which does not overlap with IL-3. IGM-2537 co-engaged with both CD123 and CD3 antigens, leading to T cell-redirected killing of AML cell lines with concomitant T cell activation."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Inflammation • Leukemia • Oncology • CD123 • IFNG • IL6 • TNFA

IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting (GlobeNewswire) - "...Highlights potent in vitro and in vivo activity with limited cytokine induction consistent with the potential for providing a favorable safety profile for a CD123-directed IgM-based T cell engager. IGM-2537 was shown to bind to human CD123 with high affinity, avidity, and specificity. IGM-2537 co-engaged with both CD123 and CD3 antigens, leading to T cell redirected killing of acute myeloid leukemia (AML) cell lines with concomitant T cell activation, and eliminated AML blast cells at physiologically relevant effector/target ratios in an ex vivo assay. IGM-2537 also showed significantly reduced cytokine release, exemplified by IFN-γ, TNF-α and IL-6, as compared to an IgG T cell engager molecule. IGM expects to file an IND application for IGM-2537 in AML in 2023."

IND • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) - "Pipeline Updates - IGM-2537 (CD123 x CD3): (i) Preclinical data for IGM-2537, the Company’s CD123 x CD3 bispecific IgM antibody, selected for poster presentation at 2022 ASH Annual Meeting and Exposition: The results will be presented on Sunday, December 11, 2022....Preclinical data will be presented highlighting potent in vitro and in vivo activity with minimal cytokine induction providing initial evidence of a favorable preclinical safety profile for a CD123 directed IgM-based T cell engager; (ii) IND application expected to be filed next year: IGM expects to file an IND application for IGM-2537 in acute myeloid leukemia in 2023."

IND • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology